DI MURO, GENESIO
DI MURO, GENESIO
Dipartimento di Scienze Cliniche e di Comunità
Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma
2025 E. Nozza, E. Emanuela, G. Di Muro, S. Di Bari, R. Catalano, G. Lopez, V. Vaira, A.M. Barbieri, G. Marra, M. Federica, T. Donatella, M. Battistin, Di Dalmazi Guido, S. Palmieri, F. Emanuele, G. Mantovani, E.M. Peverelli
AZD1775: effect of monotherapy or EDP-M combination in the treatment of ACC preclinical models
2025 E. Nozza, R. Catalano, G. Di Muro, S. Di Bari, G. Lopez, G. Marra, E. Esposito, F. Mangili, D. Treppiedi, M. Battistin, G. Mantovani, E. Peverelli
Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells
2025 D. Treppiedi, S. Di Bari, F. Mangili, A.M. Barbieri, G. Di Muro, M. Locatelli, A. Mangone, E. Peverelli, G. Mantovani
The novel SST3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells
2024 G. Di Muro, R. Catalano, D. Treppiedi, A.M. Barbieri, F. Mangili, G. Marra, S. Di Bari, E. Esposito, E. Nozza, A. Lania, M. Locatelli, D. Modena, C. Steinkuhler, E. Peverelli, G. Mantovani
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
2023 G. Di Muro, F. Mangili, E. Esposito, A.M. Barbieri, R. Catalano, D. Treppiedi, G. Marra, E. Nozza, A.G.A. Lania, E. Ferrante, M. Locatelli, M. Arosio, E. Peverelli, G. Mantovani
IGF2R: a new player in the insulin-like growth factor 2 (IGF2) pathway sustaining adrenocortical carcinoma cells growth
2023 E. Nozza, R. Catalano, E. Esposito, A.M. Barbieri, G. Marra, D. Treppiedi, G. Di Muro, F. Mangili, H. Constanze, S. Sigala, S. Palmieri, S. Frigerio, E. Ferrante, M. Arosio, G. Mantovani, E. Peverelli
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
2022 F. Mangili, E. Esposito, D. Treppiedi, R. Catalano, G. Marra, G. Di Muro, A.M. Barbieri, M. Locatelli, A.G. Lania, A. Mangone, A. Spada, M. Arosio, E. Peverelli, G. Mantovani
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
2022 D. Treppiedi, G. Marra, G. DI MURO, E. Esposito, A.M. Barbieri, R. Catalano, F. Mangili, F. Bravi, M. Locatelli, A. Gerardo Lania, E. Ferrante, R. Indirli, E. Nozza, F. Arlati, A. Spada, M. Arosio, G. Mantovani, E.M. Peverelli
A novel mechanism regulating dopamine receptor type 2 (DRD2) signal transduction in pituitary tumoral cells: the role of cAMP/PKA-induced filamin A (FLNA) phosphorylation
2021 F. Mangili, D. Treppiedi, R. Catalano, G. Marra, G. DI MURO, A. Spada, M. Arosio, E.M. Peverelli, G. Mantovani
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs
2021 D. Treppiedi, G. Di Muro, G. Marra, A.M. Barbieri, F. Mangili, R. Catalano, A. Serban, E. Ferrante, M. Locatelli, A.G. Lania, M. Arosio, A. Spada, E. Peverelli, G. Mantovani
Genetic profiling of a cohort of Italian patients with ACTH-secreting pituitary tumors and characterization of a novel USP8 gene variant
2021 D. Treppiedi, A.M. Barbieri, G. Di Muro, G. Marra, F. Mangili, R. Catalano, E. Esposito, E. Ferrante, A.L. Serban, M. Locatelli, A.G. Lania, A. Spada, M. Arosio, E. Peverelli, G. Mantovani